Kristine Glunde

Kristine Glunde

Auto-generated profile, based on publicly available information

Kristine Glunde

Division of Cancer Imaging Research, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2011 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
KGKristine Glunde
Kristine Glunde
ZBZaver Bhujwalla
Zaver Bhujwalla
SRSabrina M. Ronen
Sabrina M. Ronen

27 December 2016 in Frontiers in Oncology
Verified
Journal Article
Open access
MCMenglin Cheng
Menglin Cheng
ZBZaver M. Bhujwalla
Zaver M. Bhujwalla
KGKristine Glunde
Kristine Glunde
All cancers tested so far display abnormal choline and ethanolamine phospholipid metabolism, which has been detected with numerous magnetic resonance spectroscopy (MRS) approaches in cells, animal models of cancer, as well as the tumors of cancer patients. Since the discovery of this metabolic hallmark of cancer, many studies have been performed to elucidate the molecular origins of deregulated choline metabolism, to identify targets for cancer treatment, and to develop MRS approaches that detect choline and ethanolamine compounds for clinical use in diagnosis and treatment monitoring. Several enzymes in choline, and recently also ethanolamine, phospholipid metabolism have been identified, and their evaluation has shown that they are involved in carcinogenesis and tumor progression. Several already established enzymes as well as a number of emerging enzymes in phospholipid metabolism can be used as treatment targets for anticancer therapy, either alone or in combination with other chemotherapeutic approaches. This review summarizes the current knowledge of established and relatively novel targets in phospholipid metabolism of cancer, covering choline kinase α (ChKα), phosphatidylcholine-specific phospholipase D1 (PLD1), phosphatidylcholine-specific phospholipase C (PtdCho-PLC), sphingomyelinases (SMAs), choline transporters, glycerophosphodiesterases, phosphatidylethanolamine N-methyltransferase (PEMT), and ethanolamine kinase (ETKN). These enzymes are discussed in terms of their roles in oncogenic transformation, tumor progression, and crucial cancer cell properties such as fast proliferation, migration, and invasion. Their potential as treatment targets are evaluated based on the current literature.

11 June 2019 in NMR in Biomedicine
Verified
Journal Article
Closed access
PDF file
KSKanchan Sonkar
Kanchan Sonkar
VAVinay Ayyappan
Vinay Ayyappan
CTCaitlin M. Tressler
Caitlin M. Tressler
OAOluwatobi Adelaja
Oluwatobi Adelaja
RCRuoqing Cai
Ruoqing Cai
KGKristine Glunde
Kristine Glunde

1 November 2006 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
KGKristine Glunde
Kristine Glunde
MJMichael A Jacobs
Michael A Jacobs
ZBZaver M Bhujwalla
Zaver M Bhujwalla
Magnetic resonance studies from the last 10 years have conclusively demonstrated that choline metabolism is altered in a wide variety of cancers. In cancer, the choline metabolite profile is characterized by an elevation of phosphocholine and total choline-containing compounds. This elevation is increasingly being used as an endogenous biomarker of cancer. Importantly, the enzymes and pathways resulting in these distinct alterations in phosphocholine and total choline may provide novel molecular targets for specific, targeted anticancer therapies. In this article, we have summarized some of the magnetic resonance spectroscopy and positron emission tomography techniques that are currently available, or will be in the near future, for choline metabolism-based diagnosis, staging and therapy assessment in cancer patients. This review also outlines currently known molecular alterations that cause the aberrant choline metabolite profile in cancers and concludes with a summary of recent research findings that may, in the future, lead to novel anticancer therapies targeting choline metabolism.

1 February 2013 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
KCKamila Chughtai
Kamila Chughtai
LJLu Jiang
Lu Jiang
TGTiffany R. Greenwood
Tiffany R. Greenwood
KGKristine Glunde
Kristine Glunde
RHRon M. A. Heeren
Ron M. A. Heeren
The lipid compositions of different breast tumor microenvironments are largely unknown due to limitations in lipid imaging techniques. Imaging lipid distributions would enhance our understanding of processes occurring inside growing tumors, such as cancer cell proliferation, invasion, and metastasis. Recent developments in MALDI mass spectrometry imaging (MSI) enable rapid and specific detection of lipids directly from thin tissue sections. In this study, we performed multimodal imaging of acylcarnitines, phosphatidylcholines (PC), a lysophosphatidylcholine (LPC), and a sphingomyelin (SM) from different microenvironments of breast tumor xenograft models, which carried tdTomato red fluorescent protein as a hypoxia-response element-driven reporter gene. The MSI molecular lipid images revealed spatially heterogeneous lipid distributions within tumor tissue. Four of the most-abundant lipid species, namely PC(16:0/16:0), PC(16:0/18:1), PC(18:1/18:1), and PC(18:0/18:1), were localized in viable tumor regions, whereas LPC(16:0/0:0) was detected in necrotic tumor regions. We identified a heterogeneous distribution of palmitoylcarnitine, stearoylcarnitine, PC(16:0/22:1), and SM(d18:1/16:0) sodium adduct, which colocalized primarily with hypoxic tumor regions. For the first time, we have applied a multimodal imaging approach that has combined optical imaging and MALDI-MSI with ion mobility separation to spatially localize and structurally identify acylcarnitines and a variety of lipid species present in breast tumor xenograft models

28 April 2015 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
KGKristine Glunde
Kristine Glunde
MPMarie-France Penet
Marie-France Penet
LJLu Jiang
Lu Jiang
MJMichael A Jacobs
Michael A Jacobs
ZBZaver Bhujwalla
Zaver Bhujwalla
Abnormal choline metabolism continues to be identified in multiple cancers. Molecular causes of abnormal choline metabolism are changes in choline kinase-α, ethanolamine kinase-α, phosphatidylcholi...